Lupin has announced that its first 351(k) biologics license application in the US, for its proposed biosimilar version of Neulasta (pegfilgrastim), has been accepted for filing by the US Food and Drug Administration.
CEO Vinita Gupta said the US agency’s acceptance of the BLA for the neutropenia treatment represented “a significant achievement” for...






